Zuzana Skubalova1,2, Simona Rex1,2, Martina Sukupova1, Martin Zahalka1, Petr Skladal3, Jan Pribyl3, Hana Michalkova1,2, Akila Weerasekera4, Vojtech Adam1,2, Zbynek Heger1,2. 1. Department of Chemistry and Biochemistry, Mendel University in Brno, Brno, Czech Republic. 2. Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic. 3. Central European Institute of Technology, Masaryk University, Brno, Czech Republic. 4. Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.
Abstract
INTRODUCTION: The present study reports on examination of the effects of encapsulating the tyrosine kinase inhibitors (TKIs) vandetanib and lenvatinib into a biomacromolecular ferritin-based delivery system. METHODS: The encapsulation of TKIs was performed via two strategies: i) using an active reversible pH-dependent reassembly of ferritin´s quaternary structure and ii) passive loading of hydrophobic TKIs through the hydrophobic channels at the junctions of ferritin subunits. After encapsulation, ferritins were surface-functionalized with folic acid promoting active-targeting capabilities. RESULTS: The physico-chemical and nanomechanical analyses revealed that despite the comparable encapsulation efficiencies of both protocols, the active loading affects stability and rigidity of ferritins, plausibly due to their imperfect reassembly. Biological experiments with hormone-responsive breast cancer cells (T47-D and MCF-7) confirmed the cytotoxicity of encapsulated and folate-targeted TKIs to folate-receptor positive cancer cells, but only limited cytotoxic effects to healthy breast epithelium. Importantly, the long-term cytotoxic experiments revealed that compared to the pH-dependent encapsulation, the passively-loaded TKIs exert markedly higher anticancer activity, most likely due to undesired influence of harsh acidic environment used for the pH-dependent encapsulation on the TKIs' structural and functional properties. CONCLUSION: Since the passive loading does not require a reassembly step for which acids are needed, the presented investigation serves as a solid basis for future studies focused on encapsulation of small hydrophobic molecules.
INTRODUCTION: The present study reports on examination of the effects of encapsulating the tyrosine kinase inhibitors (TKIs) vandetanib and lenvatinib into a biomacromolecular ferritin-based delivery system. METHODS: The encapsulation of TKIs was performed via two strategies: i) using an active reversible pH-dependent reassembly of ferritin´s quaternary structure and ii) passive loading of hydrophobic TKIs through the hydrophobic channels at the junctions of ferritin subunits. After encapsulation, ferritins were surface-functionalized with folic acid promoting active-targeting capabilities. RESULTS: The physico-chemical and nanomechanical analyses revealed that despite the comparable encapsulation efficiencies of both protocols, the active loading affects stability and rigidity of ferritins, plausibly due to their imperfect reassembly. Biological experiments with hormone-responsive breast cancer cells (T47-D and MCF-7) confirmed the cytotoxicity of encapsulated and folate-targeted TKIs to folate-receptor positive cancer cells, but only limited cytotoxic effects to healthy breast epithelium. Importantly, the long-term cytotoxic experiments revealed that compared to the pH-dependent encapsulation, the passively-loaded TKIs exert markedly higher anticancer activity, most likely due to undesired influence of harsh acidic environment used for the pH-dependent encapsulation on the TKIs' structural and functional properties. CONCLUSION: Since the passive loading does not require a reassembly step for which acids are needed, the presented investigation serves as a solid basis for future studies focused on encapsulation of small hydrophobic molecules.
Authors: Lianbing Zhang; Le Li; Alessandra Di Penta; Unai Carmona; Fan Yang; Regina Schöps; Matthias Brandsch; José L Zugaza; Mato Knez Journal: Adv Healthc Mater Date: 2015-05-13 Impact factor: 9.933
Authors: B Stella; S Arpicco; M T Peracchia; D Desmaële; J Hoebeke; M Renoir; J D'Angelo; L Cattel; P Couvreur Journal: J Pharm Sci Date: 2000-11 Impact factor: 3.534
Authors: Anthony Cheung; James Opzoomer; Kristina M Ilieva; Patrycja Gazinska; Ricarda M Hoffmann; Hasan Mirza; Rebecca Marlow; Erika Francesch-Domenech; Matthew Fittall; Diana Dominguez Rodriguez; Angela Clifford; Luned Badder; Nirmesh Patel; Silvia Mele; Giulia Pellizzari; Heather J Bax; Silvia Crescioli; Gyula Petranyi; Daniel Larcombe-Young; Debra H Josephs; Silvana Canevari; Mariangela Figini; Sarah Pinder; Frank O Nestle; Cheryl Gillett; James F Spicer; Anita Grigoriadis; Andrew N J Tutt; Sophia N Karagiannis Journal: Clin Cancer Res Date: 2018-08-01 Impact factor: 12.531
Authors: Robert Mechera; Savas D Soysal; Salvatore Piscuoglio; Charlotte K Y Ng; Jasmin Zeindler; Edin Mujagic; Silvio Däster; Philippe Glauser; Henry Hoffmann; Ergin Kilic; Raoul A Droeser; Walter P Weber; Simone Muenst Journal: BMC Cancer Date: 2019-01-08 Impact factor: 4.430